CN101229272A - Medicine compounds for increasing immunizing-power, preparing method and applications thereof - Google Patents
Medicine compounds for increasing immunizing-power, preparing method and applications thereof Download PDFInfo
- Publication number
- CN101229272A CN101229272A CNA2007100630400A CN200710063040A CN101229272A CN 101229272 A CN101229272 A CN 101229272A CN A2007100630400 A CNA2007100630400 A CN A2007100630400A CN 200710063040 A CN200710063040 A CN 200710063040A CN 101229272 A CN101229272 A CN 101229272A
- Authority
- CN
- China
- Prior art keywords
- ligustri lucidi
- rhizoma fagopyri
- pharmaceutical composition
- radix ginseng
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine combination for improving immunity and a preparation method and the application thereof. The medical combination is prepared with raw herbal materials which comprise ginseng, astragalus, ligustrum lucidum, wolfberry fruits and golden buckwheat rhizome, wherein the preferable weight ratio of the ginseng, astragalus, ligustrum lucidum, wolfberry fruits and golden buckwheat rhizome is as follows: ginseng of 1 to 15 portions, astragalus of 1 to 45 portions, ligustrum lucidum of 1 to 30 portions, wolfberry fruits of 1 to 22.5 portions and golden buckwheat rhizome of 1 to 45 portions. The medicine combination of the invention has significant effect of improving the body immunity through clinical tests and good effect of improving the immunity of tumor patients, especially the tumor patients after treatment of radiotherapy and chemotherapy.
Description
Technical field
The present invention relates to pharmaceutical field, relate in particular to a kind of pharmaceutical composition that improves immunity and its production and application.
Background technology
Immunity is meant body identification and gets rid of antigenicity foreign body function that promptly body is distinguished own and non-function.Immunity mainly refers to the resistance of the anti-pathogenic microorganism of human body, and making the morbific various pathogen of people is a kind of of antigenicity foreign body, and immunity still is the important foundation stone that human body is kept ecological balance.Immunity is low is embodied in and often feels tired, easy to catch cold, wound infection, gastrointestinal upset and be subject to infectious disease attack etc. easily.
The immunity that improves human body is very important for the patient who suffers from multiple disease, especially tumor, and the immunity that improves body can significantly promote treatment of diseases and rehabilitation of patients.
See by the morbidity of the traditional Chinese medical science, the generation of any disease nothing more than just, the factor of evil two aspects.Generation about tumor, Chinese medicine is thought, is because under the state of yin and yang imbalance, qi and blood disorder, QI of five ZANG-organs disorder, external pathogen avails oneself of the opportunity to get in, destroyed the five internal organs normal physiological function, material bases such as loss human body essence, gas, blood, body fluid cause pathological changes such as the stagnation of QI, blood stasis, expectorant are coagulated, wetly stopped, poison is poly-, produce blood stasis, phlegm retention, poisonous substance etc., for a long time it, these pathological products are glued mutually, form tangible swollen thing, so tumor has just taken place.The inducement of the existing six climate exopathogens of the generation of tumor, seven emotions, impairment caused by overstrain, organism imbalance of YIN and YANG, QI and blood more have the existence of cancer poison against disorderly unusual again.Cancer poison oncogenic process is exactly constantly to consume body essence, gas, blood, body fluid, has destroyed the balance coordination of human body yang blood and qi, has reduced the anti-cancer ability of body, the diffusion rapidly of cancer poison, and the depletion that finally causes healthy energy is until death.
The common clinical treatment rule of tumor has: the body resistance strengthening and constitution consolidating method, activating blood circulation to dissipate blood stasis method, method of dissipating heat and detoxifying, hard masses softening and resolving method and treating the poisonous disease with poisonous drugs method etc.Wherein the body resistance strengthening and constitution consolidating is the cardinal principle of Chinese traditional treatment tumor.The positive deficiency of vital energy is the key factor that cancer takes place, and can occur the card of a series of deficiency of vital QI in the generation evolution of malignant tumor.As lustreless complexion, indigestion and loss of appetite abdominal distention, loose stool diarrhoea, pale tongue with thin fur, the weakness of the spleen and stomach symptom of thready pulse; Or see pharyngoxerosis, and the night sweat seminal emission, dysphoria with feverish sensation in the chest palms and soles, the red tongue tongue is few, thready and rapid pulse and having a dizzy spell, soreness of waist tinnitus, the dim eyesight order is puckery, the YIN fluid deficiency of deep red tongue tongue light and the card of the hepatic and renal YIN deficiency.Also aversion to cold and cold limbs can appear, soreness of the waist and knees, and pale complexion, clear urine in large amounts, big loose stool is thin, and light red tongue is fat, and the kidney yang of deep-thready pulse is lost the card of void.Reach an advanced stage and the cancer cachexia performance more can occur.According to treatment must aim at the pathogenesis of disease, deficiency syndrome should be treated by tonifying method, decrease benefit then principle, give replenishing QI to invigorate the spleen, enriching yin and nourishing kidney, warming and recuperating the kidney-YANG, treatments such as tonifying both YIN and YANG to improve Abwehrkraft des Koepers and immunologic function, improve symptom, the raising curative effect.In the developing of tumor, evil poison, blood stasis, expectorant can occur and pathological product such as coagulate, show as the card of deficiency in origin and excess in superficiality.Can be according to the weakened body resistance and domination of pathogen biased, giving eliminating evil is main holding concurrently to set upright, strengthening vital QI to eliminate pathogenic factors is laid equal stress on, setting upright is main holding concurrently with eliminating evil treatment.Heresy is gone to then Zhengan County, eliminating evilly promptly sets upright, and just containing then can be eliminating evil, and weakened body resistance then evil the love set upright method through treatment all the time.Therefore the body resistance strengthening and constitution consolidating is the cardinal principle of Chinese traditional treatment tumor.Operation, chemicotherapy etc. are sent an expedition against therapy and also can be damaged the human righteousness, reduce immunologic function, correct the unbalance of negative and positive in the body as cooperating traditional Chinese medical science the body resistance strengthening and constitution consolidating, not only alleviate side reaction, also can improve curative effect simultaneously.Studies show that in a large number; developing of the body resistance strengthening and constitution consolidating energy prophylaxis of cancer; the human body immunity improving function; the endocrine regulation system balancing; promote hemopoietic and protection bone marrow and conscience kidney, the infringement that alleviates chemicotherapy strengthens the ability of digesting and assimilating; the function that excites and improve the automatic adjusting of body and control automatically heightens the effect of a treatment.
At present, existing about human body immunity improving power, be specially adapted to improve the report of the pharmaceutical composition of body's immunity of tumor patient.For example, Chinese patent application numbers 200510115569.3 discloses a kind of pharmaceutical composition of human body immunity improving power, and it is made by Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii, Rhizoma Fagopyri Dibotryis and Rhizoma Curcumae.But wherein Rhizoma Curcumae has stronger toxicity, the property of medicine is fierce.
Summary of the invention
At above-mentioned the deficiencies in the prior art, the object of the present invention is to provide a kind of pharmaceutical composition of human body immunity improving power, its preparation raw material does not contain Rhizoma Curcumae.
The present invention also aims to provide the preparation method and the application thereof of aforementioned pharmaceutical compositions.
Technical conceive of the present invention is, for to Chinese number of patent application 200510115569.3 disclosed pharmaceutical compositions, as by not using the fierce medical material as Rhizoma Curcumae to improve as raw material.The inventor proposes a kind of pharmaceutical composition of improved human body immunity improving power through a large amount of tests on the basis of above-mentioned patent application document, it is made by Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis, and does not use Rhizoma Curcumae.It is to general crowd, and especially tumor patient has good immunity raising ability, is particularly suited for the postoperative tumor patient and uses, and is more suitable for cooperating chemicotherapy patient's chemicotherapy to treat use and reduce the toxic and side effects that chemicotherapy is treated.
The invention provides a kind of pharmaceutical composition of human body immunity improving power, it is made by the raw medicinal material that contains Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis, wherein, the part by weight of Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis is preferably: Radix Ginseng 1-15 part, Radix Astragali 1-45 part, Fructus Ligustri Lucidi 1-30 part, Fructus Lycii 1-22.5 part, Rhizoma Fagopyri Dibotryis 1-45 part; Preferably: Radix Ginseng 3-10 part, Radix Astragali 10-20 part, Fructus Ligustri Lucidi 7-15 part, Fructus Lycii 4-18 part, Rhizoma Fagopyri Dibotryis 10-20 part; More preferably: Radix Ginseng 4-6 part, Radix Astragali 13-17 part, Fructus Ligustri Lucidi 8-12 part, Fructus Lycii 5-10 part, Rhizoma Fagopyri Dibotryis 13-17 part; Also more preferably: Radix Ginseng 4-6 part, Radix Astragali 14-16 part, Fructus Ligustri Lucidi 9-11 part, Fructus Lycii 7-8 part, Rhizoma Fagopyri Dibotryis 14-16 part; Most preferably: 5 parts of Radix Ginsengs, 15 parts of the Radixs Astragali, 10 parts of Fructus Ligustri Lucidi, 7.5 parts of Fructus Lycii, 15 parts of Rhizoma Fagopyri Dibotryiss.
Wherein, life is preferably Radix Ginseng.
Above-mentioned raw materials Radix Ginseng (as Radix Ginseng), the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis can be bought from pharmacy, and specification meets national medical standard.
The present invention seeks to Chinese number of patent application 200510115569.3 disclosed pharmaceutical compositions are improved and finish.Behind the Rhizoma Curcumae of deletion in the raw medicinal material, the applicant finds by a large amount of tests, raw materials used medical material is carried out said ratio again after, the gained pharmaceutical composition still has good human body immunity improving power function.In the pharmaceutical composition of the present invention, the Radix Ginseng and the Radix Astragali are monarchs drug, and Fructus Ligustri Lucidi is a ministerial drug, and Fructus Lycii is an adjuvant drug, and Rhizoma Fagopyri Dibotryis is a messenger drug, and this compound basis is as follows:
Monarch drug----Radix Ginseng, the Radix Astragali: institute's its gas that gathers of heresy must be empty, the tumor patient deficiency of vital energy no matter be disease originally or modern treatment all can make it weak weakened body resistance, mainly be asthenia of qi and blood, but qi as the commander of blood, non-QI invigorating is difficult beneficial blood, so work as with QI invigorating elaboration Radix Ginseng, the Radix Astragali is monarch, makes it to set upright to get rid of evils, and modern medicine study shows, two medicines all have the effect that strengthens body immunity, and the effect that presses down tumor is indirectly arranged.
Ministerial drug----Fructus Ligustri Lucidi: the kidney being the origin of congenital constitution, in QI invigorating, strengthen kidney qi, be to make resistance against diseases stronger with mending the day after tomorrow, the malignant tumor postoperative, reaching convalescence in the radiotherapy chemotherapy all needs to set upright, eliminating evil is auxilliary, this flavor medicine merit is at kidney-boosting tonic, modern study proves and is significantly improved cellular immune function and improves the life quality effect, oleanolic acid wherein and Fructus Ligustri Lucidi polysaccharide are two kinds of active component regulating body's immunity, not only the leukopenia to chemotherapy or caused by radiation has the rising effect, also can stimulate hemopoietic function of bone marrow, improve and promote hematopoietic function.
Adjuvant drug----Fructus Lycii: sweet in the mouth is flat, returns liver, kidney channel.It has nourishing the liver and kidney, beneficial intensive culture blood, the removing nebula that makes eye bright, the effect of nourishing the lung to arrest cough.Modern pharmacology studies confirm that Fructus Lycii extract can promote cellular immune function, strengthens the formation of lymphopoiesis and tumor necrosis factor, and interleukin II is also had dual regulation.Lycium barbarum polysaccharide has radiosensitizing effect to animal, can protect mice to avoid the immunologic hypofunction that causes because of radiation injury, and the leukocyte that descends is had castering action.Be adjuvant drug in the side.
Messenger drug-----Rhizoma Fagopyri Dibotryis: function heat-clearing and toxic substances removing, activating blood circulation to dissipate blood stasis, modern pharmacy studies show that this medicament extract has tumor and the anti-tumor effect of directly pressing down, and it is synthetic to suppress tumor cell DNA, and it can suppress the invasion and attack and the transfer of multiple oncocyte, and toxicity is minimum.Evidence has the immunologic function facilitation, is main according to setting upright, and pressing down tumor is auxilliary policy, and this medicine is made antineoplastic component, is the messenger drug in the side.
The present invention also provides above-mentioned raising immunity preparation of drug combination method, this method comprises: with raw medicinal material, use water extraction respectively as Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis, to make dry extract after the extracting solution mixing, use this area conventional formulation technology (can also use excipient if necessary) to make conventional oral solid formulation, for example tablet, granule, powder, capsule, pill etc. then.
Perhaps, this method comprises: with raw medicinal material, use water extraction respectively as Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis, use this area conventional formulation technology (can also use excipient if necessary) to make conventional oral liquid extracting solution, as oral liquid etc.
In addition, can also use the corresponding preparations that is similar to Chinese patent application number 200510115569.3 disclosed methods and prepares pharmaceutical composition of the present invention, wherein need only the respective handling process of removing Rhizoma Curcumae.
As mentioned above, pharmaceutical composition of the present invention can be made various oral formulations, preferred particulates agent, capsule and oral liquid.
In preparation method of the present invention, with raw medicinal material with water extraction after the gained extracting solution mix the mixed extract obtain and make in the dry extract, can be with mixed extract by concentrating, add ethanol, filtration, gained supernatant concentration drying being made dry extract.
Pharmaceutical composition of the present invention has the effect of significant human body immunity improving power through clinical trial proof, and especially for improving tumor patient, particularly the immunity through the tumor patient of chemicotherapy treatment has extraordinary effect.
The instructions of taking of pharmaceutical composition of the present invention is: by raw medicinal material weight, take 52.5g every day, be divided into 2-3 time and use warm water delivery service.Taking 1～2 month continuously is one-period, can take continuously to consolidate curative effect.
The specific embodiment
Describe embodiments of the present invention below in conjunction with embodiment, characteristics of the present invention and advantage will be along with to the descriptions of exemplary embodiment and more clear.It will be understood by those skilled in the art that but these embodiment not delimit the scope of the invention, do not departing from the spirit and scope of the invention and can change, and change all should be within the scope of the invention like this form of the present invention and details.
Preparation embodiment
Embodiment 1 capsule
Take by weighing Radix Ginseng 5kg, Radix Astragali 15kg, Fructus Ligustri Lucidi 10kg, Fructus Lycii 7.5kg and Rhizoma Fagopyri Dibotryis 15kg, use 50L respectively, 150L, 100L, 75L and 150L decocting boil twice, decoct 2 hours at every turn, respectively the gained decoction liquor are filtered, merging filtrate, and to be concentrated into relative density be 1.15～1.20 (80 ℃), is about 50% to wherein adding ethanol to containing the alcohol amount then, stirs, static 24 hours, filter, collect supernatant, be condensed into thick paste, dry, obtain dry extract, pulverizing is also crossed 80 mesh sieves, obtains dry extract, then with an amount of calcium bicarbonate mix homogeneously, granulate with dehydrated alcohol, cross 40 mesh sieves, drying under reduced pressure, granulate, mix with an amount of magnesium stearate, fill gets capsule preparations.
Embodiment 2 granules
Take by weighing Radix Ginseng 4kg, Radix Astragali 16kg, Fructus Ligustri Lucidi 9kg, Fructus Lycii 8kg and Rhizoma Fagopyri Dibotryis 16kg use 40L respectively, 160L, 90L, 80L and 160L decocting boil twice, decoct 1.5 hours at every turn, respectively the gained decoction liquor is filtered, merging filtrate, and to be concentrated into relative density be 1.15～1.20 (80 ℃), be about 50% to wherein adding ethanol to containing the alcohol amount then, stir, static 24 hours, filter, collect supernatant, be condensed into thick paste, drying obtains dry extract, pulverize and cross 80 mesh sieves, obtain dry extract, then with an amount of Icing Sugar, dextrin and correctives mix homogeneously are granulated with dehydrated alcohol, cross 12 mesh sieves, drying under reduced pressure, granulate is packaged into granule.
Embodiment 3 oral liquids
Take by weighing Radix Ginseng 6kg, Radix Astragali 13kg, Fructus Ligustri Lucidi 12kg, Fructus Lycii 5kg and Rhizoma Fagopyri Dibotryis 17kg, boil 3 times with 60L, 130L, 120L, 50L and 170L decocting respectively, the each decoction 1.5 hours, respectively the gained decoction liquor is filtered, merging filtrate, and to be concentrated into relative density be 1.15～1.20 (80 ℃), be about 50% to wherein adding ethanol to containing the alcohol amount then, stir static 24 hours, filter, collect supernatant, concentrating under reduced pressure reclaims ethanol, adds correctives, antiseptic and mix homogeneously then, ultrafiltration then, sterilization, fill obtain oral liquid.
Embodiment 4 capsules
Take by weighing Radix Ginseng 10kg, Radix Astragali 10kg, Fructus Ligustri Lucidi 7kg, Fructus Lycii 18kg and Rhizoma Fagopyri Dibotryis 10kg, according to Chinese patent application numbers 200510115569.3 in embodiment 1 similar method make capsule, difference is, extract institute's water consumption and be respectively Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis weight 8 times, and not to the respective handling process of Rhizoma Curcumae.
Embodiment 5 oral liquids
Take by weighing Radix Ginseng 15kg, Radix Astragali 1kg, Fructus Ligustri Lucidi 1kg, Fructus Lycii 22.5kg and Rhizoma Fagopyri Dibotryis 45, according to Chinese patent application numbers 200510115569.3 in embodiment 3 similar methods make granule, difference is, extract institute's water consumption and be respectively Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis weight 10 times, and not to the respective handling process of Rhizoma Curcumae.
The test example
The clinical observation on the therapeutic effect of pharmaceutical composition of the present invention
1, test objective
Observe the influence of pharmaceutical composition of the present invention, the synergism and attenuation of chemicotherapy after performing the operation to the raising of patient's life quality and to tumor patient to tumor patient immunity.
2, data and method
1.1 subjects
Patient's 40 examples are divided into test group and matched group at random, every group 20 people.Male 17 examples in the test, women 23 examples; 32～72 years old age, average 51 years old.Breast carcinoma 9 examples wherein, pulmonary carcinoma 17 examples, rectal cancer 6 examples, ovarian cancer 3 examples, the esophageal carcinoma 5 examples.All case meets the diagnostic criteria of malignant tumor all through clinical, biochemical, iconography, cytology and pathological diagnosis.
1.2 Therapeutic Method
All case all adopts the method for chemotherapy to the ill, and test group adds the medicine with the embodiment of the invention 1, and every day twice, every day, dosage was the 52.5g crude drug.All case difference venous blood collection before and after treatment is inspected t lymphocyte subset group CD by ready samples
4 +, CD
8 +And natural killer cell (NK cell).
1.3 observation index and evaluation criteria
1.3.1 toxicity of chemotherapy: according to the evaluation of World Health Organization (WHO) toxicity of anticancer agents reaction normal, observe haematics toxicity and gastrointestinal reaction, after chemotherapy began, routine blood test checked once in per 4 days, finished to whole test.
1.3.2 immunologic function evaluation: immune indexes is mainly observed t lymphocyte subset group CD
4 +, CD
8,
+, CD
4 +/ CD
8 +And the variation of natural killer cell (NK cell).
13.3 life quality evaluation: Quality Of Well Being Index is observed according to the listed index of karnofsky point system, and for improving, reducing greater than 10 fens persons was reduction greater than 10 fens persons in the increase of marking before controlling after all controlling, and increased or reduced less than 10 fens persons to stablizing.Observe simultaneously and have or not untoward reaction such as heating, gastrointestinal reaction, hepatic and renal function be unusual.
1.4 statistical method
Test data adopts spssl0.0 software to carry out statistical analysis, and measurement data is represented with x ± s, relatively adopts the t check between group, and different time points relatively adopt one factor analysis of variance in the group, and (p＜0.05) is for there being significant difference.
2 results
2.1 the comparison of chemotherapeutic toxicity before and after the treatment
Test group and matched group leukocyte count all have decline before than chemotherapy, but the amplitude of test group leukopenia is little than the matched group amplitude, and the time of recovering normal value shorten, the two relatively has significant difference (p＜0.05).See the following form one.
The variation of leukocyte count, hemoglobin content and platelet count relatively in table one test group and the matched group test front and back blood
(x±s)
| Test period | Leukocyte count (* 10 9/L) | Hemoglobin content (g/L) | Platelet count (* 10 9/L) |
| Test group (conventional chemotherapy+oral embodiment 1 capsule) | |||
| Before the chemotherapy | 6.4±1.4 | 120.9±11.5 | 183.6±49.5 |
| After the chemotherapy 4 days | 6.2±2.4 | 108.2±12.3 | 158.2±66.3 |
| After the chemotherapy 8 days | 5.6±1.8 | 106.6±13.6 | 155.7±58.8 |
| After the chemotherapy 12 days | 3.9±2.1 | 107.8±11.5 | 166.8±56.6 |
| After the chemotherapy 16 days | 4.3±1.9 | 110.3±13.0 | 177.1±51.5 |
| Matched group (conventional chemotherapy) | |||
| Before the chemotherapy | 6.6±1.2 | 122.0±12.1 | 180.9±51.8 |
| After the chemotherapy 4 days | 5.3±2.6 * | 106.3±14.8 | 160.1±57.5 |
| After the chemotherapy 8 days | 3.5±2.5 * | 96.2±13.5 | 144.8±61.1 |
| After the chemotherapy 12 days | 2.4±1.4 * | 94.8±12.7 * | 138.7±47.3 |
| After the chemotherapy 16 days | 3.1±2.2 * | 100.1±16.5 | 140.6±54.9 |
Annotate:
*Compare with identical schedule after the test period chemotherapy p＜0.05.
2.2 the variation of immunity before and after the treatment
Treatment pre-T lymphocyte subgroup constitutes there was no significant difference between two groups; Treatment back test group CD
4 +, CD
8,
+, CD
4 +/ CD
8 +And all obviously risings of NK cell, relatively preceding with treatment, significant difference p＜0.05 is arranged, These parameters then is starkly lower than test group after the treatment of control group.Specifically see the following form two.
T lymphocyte subset group and NK cellular change are relatively before and after table two test group and the matched group test
(x±s)
| Group | CD 4 + | CD 8 + | CD 4 +/CD 8 + | NK |
| Test group | ||||
| Before the treatment | 33.28±4.36 | 23.43±5.16 | 1.19±0.88 | 33.24±11.52 |
| After the treatment | 38.49±5.53 ** | 25.14±4.52 | 1.81±0.69 ** | 52.92±8.58 * |
| Matched group | ||||
| Before the treatment | 34.94±5.15 | 22.96±4.38 | 1.06±0.75 | 34.68±9.67 |
| After the treatment | 33.29±4.47 | 20.47±5.65 | 0.93±0.68 | 30.66±10.53 |
Annotate:
*P＜0.01,
*P＜0.05, relatively preceding with treatment.
2.3 the variation of life quality before and after the treatment
Test group: life quality improves 13 examples, and life quality is stablized 5 examples, life quality 2 examples that descend.
Matched group: life quality improves 8 examples, and life quality is stablized 3 examples, life quality 9 examples that descend.
Test group obviously is better than matched group (p＜0.05) to the improvement of life quality.
Nausea and vomiting 3 examples appear in the test group, unusual 2 examples of hepatic and renal function, 2 examples of generating heat; Heating 3 examples appear in matched group, unusual 3 examples of hepatic and renal function, and nausea and vomiting 4 examples, two groups untoward reaction difference is not remarkable.
3, conclusion
Drug regimen of the present invention is the toxic reaction that brings of ameliorate tumor patient chemicotherapy effectively, the hemopoietic function of protection bone marrow, and particularly the leukopenia that chemotherapeutics is caused has good antagonism.Can also significantly improve simultaneously the immunity of tumor patient, obviously improve the symptom of patients undergoing chemotherapy, improve chemotherapeutic period patient's life quality.
Claims (10)
1. pharmaceutical composition that improves immunity, it is made by the raw medicinal material that contains Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis, wherein, the part by weight of Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis is: Radix Ginseng 1-15 part, Radix Astragali 1-45 part, Fructus Ligustri Lucidi 1-30 part, Fructus Lycii 1-22.5 part, Rhizoma Fagopyri Dibotryis 1-45 part.
2. according to the pharmaceutical composition of claim 1, it is characterized in that the weight proportion of Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis is: Radix Ginseng 3-10 part, Radix Astragali 10-20 part, Fructus Ligustri Lucidi 7-15 part, Fructus Lycii 4-18 part, Rhizoma Fagopyri Dibotryis 10-20 part.
3. according to the pharmaceutical composition of claim 1, it is characterized in that the weight proportion of Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis is: Radix Ginseng 4-6 part, Radix Astragali 13-17 part, Fructus Ligustri Lucidi 8-12 part, Fructus Lycii 5-10 part, Rhizoma Fagopyri Dibotryis 13-17 part.
4. according to the pharmaceutical composition of claim 1, it is characterized in that the weight proportion of Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis is: Radix Ginseng 4-6 part, Radix Astragali 14-16 part, Fructus Ligustri Lucidi 9-11 part, Fructus Lycii 7-8 part, Rhizoma Fagopyri Dibotryis 14-16 part.
5. according to the pharmaceutical composition of claim 1, it is characterized in that the weight proportion of Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis is: 5 parts of Radix Ginsengs, 15 parts of the Radixs Astragali, 10 parts of Fructus Ligustri Lucidi, 7.5 parts of Fructus Lycii, 15 parts of Rhizoma Fagopyri Dibotryiss.
6. according to each pharmaceutical composition of claim 1-5, it is characterized in that wherein said Radix Ginseng is a Radix Ginseng.
7. according to each pharmaceutical composition of claim 1-6, it is characterized in that the dosage form of described pharmaceutical composition is an oral formulations, as tablet, granule, powder, capsule, pill and oral liquid etc.
8. method for the treatment of each pharmaceutical composition of claim 1-6, this method comprises: with raw medicinal material, use water extraction respectively as Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis, to make dry extract after the extracting solution mixing, use this area conventional formulation technology (can also use excipient if necessary) to make conventional oral solid formulation, for example tablet, granule, powder, capsule, pill etc. then.
9. method for the treatment of each pharmaceutical composition of claim 1-6, this method comprises: with raw medicinal material, use water extraction respectively as Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii and Rhizoma Fagopyri Dibotryis, use this area conventional formulation technology (can also use excipient if necessary) to make conventional oral liquid extracting solution, as oral liquid etc.
10. each pharmaceutical composition of claim 1-6 improves immunity in preparation, especially improves tumor patient immunity, particularly improves chemicotherapy tumor patient immunity, perhaps alleviates the application in the medicine of toxic and side effects of chemoradiotherapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100630400A CN101229272A (en) | 2007-01-25 | 2007-01-25 | Medicine compounds for increasing immunizing-power, preparing method and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100630400A CN101229272A (en) | 2007-01-25 | 2007-01-25 | Medicine compounds for increasing immunizing-power, preparing method and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101229272A true CN101229272A (en) | 2008-07-30 |
Family
ID=39896286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007100630400A Pending CN101229272A (en) | 2007-01-25 | 2007-01-25 | Medicine compounds for increasing immunizing-power, preparing method and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101229272A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109984343A (en) * | 2019-04-02 | 2019-07-09 | 湖南德雅医药科技有限公司 | A kind of compound ginseng polyoses grain for improving immunity and mitigating tumor chemoradiotherapy reaction |
| WO2022057499A1 (en) * | 2020-09-18 | 2022-03-24 | 江苏康缘药业股份有限公司 | Composition and preparation method for same |
-
2007
- 2007-01-25 CN CNA2007100630400A patent/CN101229272A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109984343A (en) * | 2019-04-02 | 2019-07-09 | 湖南德雅医药科技有限公司 | A kind of compound ginseng polyoses grain for improving immunity and mitigating tumor chemoradiotherapy reaction |
| WO2022057499A1 (en) * | 2020-09-18 | 2022-03-24 | 江苏康缘药业股份有限公司 | Composition and preparation method for same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008650B (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN102698207A (en) | Traditional Chinese medicine composition for treating hepatopathy and preparation method thereof | |
| CN102526635B (en) | Medicament for treating premenstrual stress syndrome and preparation method thereof | |
| CN104435837A (en) | Pharmaceutical composition for treating spontaneous perspiration and night sweat | |
| CN104288624A (en) | Pharmaceutical composition and application thereof | |
| CN102772611A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN102145127A (en) | Medicament for treating rheumatoid arthritis and preparation method thereof | |
| US7381430B2 (en) | Pharmaceutical composition comprising a combination of Chinese traditional medicines | |
| CN102552519B (en) | Chinese medicine composition for activating blood and stopping pain, preparation process and application | |
| CN101229272A (en) | Medicine compounds for increasing immunizing-power, preparing method and applications thereof | |
| CN101199749A (en) | Chinese medicine for treating AIDS | |
| CN103272159A (en) | Chinese herbal preparation used for treating consumptive disease and preparation method thereof | |
| CN106581299B (en) | Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof | |
| CN106620516A (en) | Traditional Chinese medicine composition used for health maintenance and weight loss as well as preparation and preparation method thereof | |
| CN106511838A (en) | Traditional Chinese medicinal granules for treating alcoholic liver injury | |
| CN107929413B (en) | Anti-fatigue traditional Chinese medicine composition and application and preparation method thereof | |
| CN101690746B (en) | Chinese herbal preparation for treating soft tissue injuries and fractures | |
| CN100348259C (en) | Medicine composition for raising immunity and its prepn and application | |
| CN102139015B (en) | Medicinal liquor capable of balancing yin and yang and improving immunity and preparation thereof | |
| CN101007114B (en) | An adjuvant drug or health food for tumor patients and preparation thereof | |
| CN116211987B (en) | Traditional Chinese medicine composition for treating refractory endocrine drug-resistant breast cancer, traditional Chinese medicine preparation and application thereof | |
| CN100540033C (en) | A kind of externally-applied health-care products that is used for hepatitis B recuperating medicine and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080730 |